• 1
    Schwarz EM, Looney RJ, O'Keefe RJ 2000 Anti-TNF-alpha therapy as a clinical intervention for periprosthetic osteolysis. Arthritis Res 2: 165168.
  • 2
    Callaghan JJ, Forest EE, Olejniczak JP, Goetz DD, Johnston RC 1998 Charnley total hip arthroplasty in patients less than fifty years old. A twenty to twenty-five-year follow-up note. J Bone Joint Surg Am 80: 704714.
  • 3
    Fender D, Harper WM, Gregg PJ 1999 Outcome of Charnley total hip replacement across a single health region in England: The results at five years from a regional hip register. J Bone Joint Surg Br 81: 577581.
  • 4
    Margevicius KJ, Bauer TW, McMahon JT, Brown SA, Merritt K 1994 Isolation and characterization of debris in membranes around total joint prostheses. J Bone Joint Surg Am 76: 16641675.
  • 5
    Hirakawa K, Bauer TW, Stulberg BN, Wilde AH 1996 Comparison and quantitation of wear debris of failed total hip and total knee arthroplasty. J Biomed Mater Res 31: 257263.
  • 6
    Hirakawa K, Bauer TW, Stulberg BN, Wilde AH, Secic M 1996 Characterization and comparison of wear debris from failed total hip implants of different types. J Bone Joint Surg Am 78: 12351243.
  • 7
    Looney RJ, Boyd A, Totterman S, Seo GS, Tamez-Pena J, Campbell D, Novotny L, Olcott C, Martell J, Hayes FA, O'Keefe RJ, Schwarz EM 2002 Volumetric computerized tomography as a measurement of periprosthetic acetabular osteolysis and its correlation with wear. Arthritis Res 4: 5963.
  • 8
    Oparaugo PC, Clarke IC, Malchau H, Herberts P 2001 Correlation of wear debris-induced osteolysis and revision with volumetric wear-rates of polyethylene: A survey of 8 reports in the literature. Acta Orthop Scand 72: 2228.
  • 9
    Jiranek WA, Machado M, Jasty M, Jevsevar D, Wolfe HJ, Goldring SR, Goldberg MJ, Harris WH 1993 Production of cytokines around loosened cemented acetabular components. Analysis with immunohistochemical techniques and in situ hybridization. J Bone Joint Surg Am 75: 863879.
  • 10
    Perry MJ, Mortuza FY, Ponsford FM, Elson CJ, Atkins RM 1995 Analysis of cell types and mediator production from tissues around loosening joint implants. Br J Rheumatol 34: 11271134.
  • 11
    Udagawa N, Kotake S, Kamatani N, Takahashi N, Suda T 2002 The molecular mechanism of osteoclastogenesis in rheumatoid arthritis. Arthritis Res 4: 281289.
  • 12
    Kotake S, Udagawa N, Hakoda M, Mogi M, Yano K, Tsuda E, Takahashi K, Furuya T, Ishiyama S, Kim KJ, Saito S, Nishikawa T, Takahashi N, Togari A, Tomatsu T, Suda T, Kamatani N 2001 Activated human T cells directly induce osteoclastogenesis from human monocytes: Possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthritis Rheum 44: 10031012.
  • 13
    Perlman H, Bradley K, Liu H, Cole S, Shamiyeh E, Smith RC, Walsh K, Fiore S, Koch AE, Firestein GS, Haines GK III, Pope RM 2003 IL-6 and matrix metalloproteinase-1 are regulated by the cyclin-dependent kinase inhibitor p21 in synovial fibroblasts. J Immunol 170: 838845.
  • 14
    van der Laan WH, Quax PH, Seemayer CA, Huisman LG, Pieterman EJ, Grimbergen JM, Verheijen JH, Breedveld FC, Gay RE, Gay S, Huizinga TW, Pap T 2003 Cartilage degradation and invasion by rheumatoid synovial fibroblasts is inhibited by gene transfer of TIMP-1 and TIMP-3. Gene Ther 10: 234242.
  • 15
    Ritchlin C 2000 Fibroblast biology. Effector signals released by the synovial fibroblast in arthritis. Arthritis Res 2: 356360.
  • 16
    Takayanagi H, Iizuka H, Juji T, Nakagawa T, Yamamoto A, Miyazaki T, Koshihara Y, Oda H, Nakamura K, Tanaka S 2000 Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum 43: 259269.
  • 17
    Glant TT, Jacobs JJ, Mikecz K, Yao J, Chubinskaja S, Williams JM, Urban RL, Shanbhag AS, Lee SH, Sumner DR 1996 Particulate-Induced, Prostaglandin- and Cytokine-Mediated Bone Resorption in an Experimental System and in Failed Joint Replacements. Am J Ther 3: 2741.
  • 18
    Bukata SV, Gelinas J, Wei X, Rosier RN, Puzas JE, Zhang X, Schwarz EM, Song XR, Griswold DE, O'Keefe RJ 2003 PGE2 and IL-6 production by fibroblasts in response to titanium wear debris particles is mediated through a COX-2 dependent pathway. J Orthop Res 22: 612.
  • 19
    Zhang X, Morham SG, Langenbach R, Young DA, Xing L, Boyce B, Puzas EJ, Rosier RN, O'Keefe RJ, Schwarz EM 2001 Evidence for a direct role of cyclo-oxygenase 2 in implant wear debris-induced osteolysis. J Bone Miner Res 16: 660670.
  • 20
    Mandelin J, Li TF, Liljestrom M, Kroon ME, Hanemaaijer R, Santavirta S, Konttinen YT 2003 Imbalance of RANKL/RANK/OPG system in interface tissue in loosening of total hip replacement. J Bone Joint Surg Br 85: 11961201.
  • 21
    Sakai H, Jingushi S, Shuto T, Urabe K, Ikenoue T, Okazaki K, Kukita T, Kukita A, Iwamoto Y 2002 Fibroblasts from the inner granulation tissue of the pseudocapsule in hips at revision arthroplasty induce osteoclast differentiation, as do stromal cells. Ann Rheum Dis 61: 103109.
  • 22
    Huang JC, Sakata T, Pfleger LL, Bencsik M, Halloran BP, Bikle DD, Nissenson RA 2004 PTH differentially regulates expression of RANKL and OPG. J Bone Miner Res 19: 235244.
  • 23
    Rubin J, Ackert-Bicknell CL, Zhu L, Fan X, Murphy TC, Nanes MS, Marcus R, Holloway L, Beamer WG, Rosen CJ 2002 IGF-I regulates osteoprotegerin (OPG) and receptor activator of nuclear factor-kappaB ligand in vitro and OPG in vivo. J Clin Endocrinol Metab 87: 42734279.
  • 24
    Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, Timms E, Tan HL, Elliott G, Kelley MJ, Sarosi I, Wang L, Xia XZ, Elliott R, Chiu L, Black T, Scully S, Capparelli C, Morony S, Shimamoto G, Bass MB, Boyle WJ 1999 Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 96: 35403545.
  • 25
    Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T 1998 Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95: 35973602.
  • 26
    Hofbauer LC, Heufelder AE 2001 Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology. J Mol Med 79: 243253.
  • 27
    Childs L, Paschalis EP, Xing L, Dougall WC, Anderson D, Boskey AL, Puzas JE, Rosier RN, O'Keefe RJ, Boyce BF, Schwarz EM 2002 In vivo RANK signaling blockade using the receptor activator of NF-kappaB: Fc effectively prevents and ameliorates wear debris-induced osteolysis via osteoclast depletion without inhibiting osteogenesis. J Bone Miner Res 17: 192199.
  • 28
    Zhang X, Morham SG, Langenbach R, Young DA 1999 Malignant transformation and antineoplastic actions of nonsteroidal antiinflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblasts. J Exp Med 190: 451460.
  • 29
    Li P, Sanz I, O'Keefe RJ, Schwarz EM 2000 NF-kappa B regulates VCAM-1 expression on fibroblast-like synoviocytes. J Immunol 164: 59905997.
  • 30
    Bi Y, Seabold JM, Kaar SG, Ragab AA, Goldberg VM, Anderson JM, Greenfield EM 2001 Adherent endotoxin on orthopedic wear particles stimulates cytokine production and osteoclast differentiation. J Bone Miner Res 16: 20822091.
  • 31
    Ionescu AM, Schwarz EM, Vinson C, Puzas JE, Rosier RN, Reynolds PR, O'Keefe RJ 2001 PTHrP modulates chondrocyte differentiation through AP-1 and CREB signaling. J Biol Chem 276: 1163911647.
  • 32
    Nakashima T, Kobayashi Y, Yamasaki S, Kawakami A, Eguchi K, Sasaki H, Sakai H 2000 Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: Modulation of the expression by osteotropic factors and cytokines. Biochem Biophys Res Commun 275: 768775.
  • 33
    Li P, Schwarz EM, O'Keefe RJ, Ma L, Boyce BF, Xing L 2004 RANK signaling is not required for TNFalpha-mediated increase in CD11(hi) osteoclast precursors but is essential for mature osteoclast formation in TNFalpha-mediated inflammatory arthritis. J Bone Miner Res 19: 207213.
  • 34
    Frick KK, Bushinsky DA 2003 Metabolic acidosis stimulates RANKL RNA expression in bone through a cyclo-oxygenase-dependent mechanism. J Bone Miner Res 18: 13171325.
  • 35
    Cheng B, Kato Y, Zhao S, Luo J, Sprague E, Bonewald LF, Jiang JX 2001 PGE(2) is essential for gap junction-mediated intercellular communication between osteocyte-like MLO-Y4 cells in response to mechanical strain. Endocrinology 142: 34643473.
  • 36
    Jones LC, Frondoza C, Hungerford DS 1999 Immunohistochemical evaluation of interface membranes from failed cemented and uncemented acetabular components. J Biomed Mater Res 48: 889898.
  • 37
    Ulrich-Vinther M, Carmody EE, Goater JJ, Sb K, O'Keefe RJ, Schwarz EM 2002 Recombinant adeno-associated virus-mediated osteoprotegerin gene therapy inhibits wear debris-induced osteolysis. J Bone Joint Surg Am 84: 14051412.
  • 38
    Fujino H, Xu W, Regan JW 2003 Prostaglandin E2 induced functional expression of early growth response factor-1 by EP4, but not EP2, prostanoid receptors via the phosphatidylinositol 3-kinase and extracellular signal-regulated kinases. J Biol Chem 278: 1215112156.
  • 39
    Hatae N, Sugimoto Y, Ichikawa A 2002 Prostaglandin receptors: Advances in the study of EP3 receptor signaling. J Biochem (Tokyo) 131: 781784.
  • 40
    Nguyen M, Solle M, Audoly LP, Tilley SL, Stock JL, McNeish JD, Coffman TM, Dombrowicz D, Koller BH 2002 Receptors and signaling mechanisms required for prostaglandin E2-mediated regulation of mast cell degranulation and IL-6 production. J Immunol 169: 45864593.
  • 41
    Kiriyama M, Ushikubi F, Kobayashi T, Hirata M, Sugimoto Y, Narumiya S 1997 Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol 122: 217224.
  • 42
    Ndukwu IM, White SR, Leff AR, Mitchell RW 1997 EP1 receptor blockade attenuates both spontaneous tone and PGE2-elicited contraction in guinea pig trachealis. Am J Physiol 273: L626L633.
  • 43
    Reinheimer T, Harnack E, Racke K, Wessler I 1998 Prostanoid receptors of the EP3 subtype mediate inhibition of evoked [3H]acetylcholine release from isolated human bronchi. Br J Pharmacol 125: 271276.
  • 44
    Walch L, de Montpreville V, Brink C, Norel X 2001 Prostanoid EP(1)- and TP-receptors involved in the contraction of human pulmonary veins. Br J Pharmacol 134: 16711678.
  • 45
    Woodiel FN, Fall PM, Raisz LG 1996 Anabolic effects of prostaglandins in cultured fetal rat calvariae: Structure-activity relations and signal transduction pathway. J Bone Miner Res 11: 12491255.
  • 46
    Regan JW 2003 EP2 and EP4 prostanoid receptor signaling. Life Sci 74: 143153.
  • 47
    Caughey GE, Cleland LG, Penglis PS, Gamble JR, James MJ 2001 Roles of cyclooxygenase (COX)-1 and COX-2 in prostanoid production by human endothelial cells: Selective up-regulation of prostacyclin synthesis by COX-2. J Immunol 167: 28312838.
  • 48
    Morita I 2002 Distinct functions of COX-1 and COX-2. Prostaglandins Other Lipid Mediat 68–69: 165175.
  • 49
    Smith WL, DeWitt DL, Garavito RM 2000 Cyclooxygenases: Structural, cellular, and molecular biology. Annu Rev Biochem 69: 145182.
  • 50
    Everts B, Wahrborg P, Hedner T 2000 COX-2-Specific inhibitors-the emergence of a new class of analgesic and anti-inflammatory drugs. Clin Rheumatol 19: 331343.
  • 51
    Ohnishi A, Shimamoto C, Katsu K, Ito S, Imai Y, Nakahari T 2001 EP1 and EP4 receptors mediate exocytosis evoked by prostaglandin E(2) in guinea-pig antral mucous cells. Exp Physiol 86: 451460.
  • 52
    Liang Y, Nakamura S, Cui L, Johkura K, Ogiwara N, Sasaki K 2004 Three-dimensional expression of adhesion molecules on the superficial synovial intima of LPS-induced arthritis of the mouse knee analyzed by immuno-SEM. J Electron Microsc (Tokyo) 53: 9397.
  • 53
    Bradfield PF, Amft N, Vernon-Wilson E, Exley AE, Parsonage G, Rainger GE, Nash GB, Thomas AM, Simmons DL, Salmon M, Buckley CD 2003 Rheumatoid fibroblast-like synoviocytes overexpress the chemokine stromal cell-derived factor 1 (CXCL12), which supports distinct patterns and rates of CD4+ and CD8+ T cell migration within synovial tissue. Arthritis Rheum 48: 24722482.
  • 54
    Croft D, McIntyre P, Wibulswas A, Kramer I 1999 Sustained elevated levels of VCAM-1 in cultured fibroblast-like synoviocytes can be achieved by TNF-alpha in combination with either IL-4 or IL-13 through increased mRNA stability. Am J Pathol 154: 11491158.
  • 55
    Childs LM, Goater JJ, O'Keefe RJ, Schwarz EM 2001 Efficacy of Etanercept for wear debris-induced osteolysis. J Bone Miner Res 16: 338347.
  • 56
    Lohmann CH, Schwartz Z, Koster G, Jahn U, Buchhorn GH, MacDougall MJ, Casasola D, Liu Y, Sylvia VL, Dean DD, Boyan BD 2000 Phagocytosis of wear debris by osteoblasts affects differentiation and local factor production in a manner dependent on particle composition. Biomaterials 21: 551561.
  • 57
    Wong N, Trindade MC, Patel R, Yaszay B, Goodman SB, Smith RL 2004 Effects of interleukin-10 on titanium particle-induced macrophage transcription factor activation and cytokine expression in vitro. J Biomed Mater Res 69A: 4046.
  • 58
    Ninomiya JT, Struve JA, Stelloh CT, Toth JM, Crosby KE 2001 Effects of hydroxyapatite particulate debris on the production of cytokines and proteases in human fibroblasts. J Orthop Res 19: 621628.
  • 59
    Wooley PH, Morren R, Andary J, Sud S, Yang SY, Mayton L, Markel D, Sieving A, Nasser S 2002 Inflammatory responses to orthopaedic biomaterials in the murine air pouch. Biomaterials 23: 517526.
  • 60
    Nakashima Y, Sun DH, Trindade MC, Maloney WJ, Goodman SB, Schurman DJ, Smith RL 1999 Signaling pathways for tumor necrosis factor-alpha and interleukin-6 expression in human macrophages exposed to titanium-alloy particulate debris in vitro. J Bone Joint Surg Am 81: 603615.
  • 61
    Kitazawa S, Kajimoto K, Kondo T, Kitazawa R 2003 Vitamin D3 supports osteoclastogenesis via functional vitamin D response element of human RANKL gene promoter. J Cell Biochem 89: 771777.
  • 62
    Quinn JM, Horwood NJ, Elliott J, Gillespie MT, Martin TJ 2000 Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation. J Bone Miner Res 15: 14591466.
  • 63
    Palmqvist P, Persson E, Conaway HH, Lerner UH 2002 IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae. J Immunol 169: 33533362.
  • 64
    Atkins GJ, Kostakis P, Pan B, Farrugia A, Gronthos S, Evdokiou A, Harrison K, Findlay DM, Zannettino AC 2003 RANKL expression is related to the differentiation state of human osteoblasts. J Bone Miner Res 18: 10881098.
  • 65
    Quinn JM, Itoh K, Udagawa N, Hausler K, Yasuda H, Shima N, Mizuno A, Higashio K, Takahashi N, Suda T, Martin TJ, Gillespie MT 2001 Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions. J Bone Miner Res 16: 17871794.
  • 66
    Li X, Pilbeam CC, Pan L, Breyer RM, Raisz LG 2002 Effects of prostaglandin E2 on gene expression in primary osteoblastic cells from prostaglandin receptor knockout mice. Bone 30: 567573.
  • 67
    Li X, Tomita M, Pilbeam CC, Breyer RM, Raisz LG 2002 Prostaglandin receptor EP2 mediates PGE2 stimulated hypercalcemia in mice in vivo. Prostaglandins Other Lipid Mediat 67: 173180.
  • 68
    Wada N, Maeda H, Yoshimine Y, Akamine A 2004 Lipopolysaccharide stimulates expression of osteoprotegerin and receptor activator of NF-kappa B ligand in periodontal ligament fibroblasts through the induction of interleukin-1 beta and tumor necrosis factor-alpha. Bone 35: 629635.
  • 69
    Sen M, Chamorro M, Reifert J, Corr M, Carson DA 2001 Blockade of Wnt-5A/frizzled 5 signaling inhibits rheumatoid synoviocyte activation. Arthritis Rheum 44: 772781.